Pediatric Brain Tumor Foundation celebrates FDA approval of Day One Biopharmaceuticals™ OJEMDA„, new treatment for common pediatric brain tumor type
XOMA is entitled to a mid-single digit royalty on global OJEMDA„ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...
Day One drug for common childhood brain tumor approved by FDA
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One's OJEMDA„ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Co
XOMA Earns $5M Milestone Upon Acceptance of Day One™s Tovorafenib NDA for pLGG
The FDA has granted priority review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024.
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment ...
BRISBANE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), please note that in the second...
Seven months after Day One posted positive initial data for its brain tumor drug, the therapy still appears to be on track for success—proving its effectiveness in a phase 2 trial.